Menu

Biology, Genetics & Bone Healing MCQs

Practice Set 79 of 212

This practice set contains high-yield board review questions covering key concepts in Biology, Genetics & Bone Healing. Each clinical scenario is designed to test your diagnostic and management skills relevant to this subspecialty.

Question 1561

Topic: Biology, Genetics & Bone Healing

Bone morphogenetic proteins (BMPs) play a crucial role in osteoinduction and fracture healing. They exert their intracellular effects primarily by binding to which of the following types of cell-surface receptors?

. Tyrosine kinase receptors
. G-protein coupled receptors
. Serine/threonine kinase receptors
. Intracellular nuclear receptors
. Ligand-gated ion channels

Correct Answer & Explanation

. Tyrosine kinase receptors

Explanation

BMPs are members of the transforming growth factor-beta (TGF-β) superfamily. They bind to cell surface receptors that have intrinsic serine/threonine kinase activity. Upon activation, these receptors phosphorylate intracellular Smad proteins (e.g., Smad 1, 5, 8), which then complex with Smad 4 and translocate to the nucleus to regulate target gene transcription.

Question 1562

Topic: Biology, Genetics & Bone Healing

Denosumab is an effective pharmacological agent used in the management of osteoporosis, bone metastases, and unresectable giant cell tumors of bone. It decreases bone resorption by directly targeting and inhibiting which of the following?

. RANK receptor
. RANKL
. Osteoprotegerin (OPG)
. Cathepsin K
. Sclerostin

Correct Answer & Explanation

. RANK receptor

Explanation

Denosumab is a fully human monoclonal antibody that binds directly to RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand) with high affinity. By neutralizing RANKL, it prevents RANKL from binding to the RANK receptor on the surface of osteoclast precursors and mature osteoclasts, thereby inhibiting osteoclast formation, function, and survival.

Question 1563

Topic: Biology, Genetics & Bone Healing

Vitamin D homeostasis is critical for normal bone mineralization. Which enzyme is responsible for the conversion of 25-hydroxyvitamin D to its most physiologically active form, 1,25-dihydroxyvitamin D, and where does this primarily occur?

. 25-hydroxylase in the liver
. 1-alpha-hydroxylase in the liver
. 1-alpha-hydroxylase in the kidney
. 24-hydroxylase in the kidney
. 25-hydroxylase in the skin

Correct Answer & Explanation

. 25-hydroxylase in the liver

Explanation

The most biologically active form of vitamin D is 1,25-dihydroxyvitamin D. The final, tightly regulated step of its synthesis is the hydroxylation of 25-hydroxyvitamin D by the enzyme 1-alpha-hydroxylase. This conversion occurs primarily in the proximal convoluted tubules of the kidney, and the enzyme's activity is upregulated by parathyroid hormone (PTH) and hypophosphatemia.

Question 1564

Topic: Biology, Genetics & Bone Healing

Vitamin C deficiency (scurvy) profoundly affects bone and connective tissue formation, leading to poor wound healing, capillary fragility, and defective osteoid matrix. This occurs because ascorbic acid is an essential cofactor in which specific step of collagen synthesis?

. Transcription of procollagen genes in the nucleus
. Cleavage of terminal registration peptides in the extracellular space
. Hydroxylation of proline and lysine residues within the rough endoplasmic reticulum
. Glycosylation of hydroxylysine residues in the Golgi apparatus
. Covalent cross-linking of tropocollagen molecules by lysyl oxidase

Correct Answer & Explanation

. Transcription of procollagen genes in the nucleus

Explanation

Vitamin C (ascorbic acid) acts as an essential reducing agent for the enzymes prolyl hydroxylase and lysyl hydroxylase. These enzymes are responsible for the hydroxylation of proline and lysine residues on the nascent procollagen alpha chains within the rough endoplasmic reticulum. Without this hydroxylation, the collagen chains cannot form a stable triple helix at body temperature, leading to rapid degradation and weak connective tissue.

Question 1565

Topic: Biology, Genetics & Bone Healing

A 45-year-old male smoker is undergoing a single-level anterior lumbar interbody fusion (ALIF). The surgeon decides to use a commercially available recombinant human bone morphogenetic protein (rhBMP) to enhance fusion. Which of the following best describes the intracellular signaling mechanism of the FDA-approved rhBMP used for this indication?

. Binding to a tyrosine kinase receptor, triggering the MAPK cascade
. Binding to a serine/threonine kinase receptor, activating the SMAD pathway
. Inhibiting RANKL, reducing osteoclast-mediated bone resorption
. Binding to the Wnt receptor, stabilizing beta-catenin
. Activating adenylyl cyclase, increasing intracellular cAMP

Correct Answer & Explanation

. Binding to a tyrosine kinase receptor, triggering the MAPK cascade

Explanation

rhBMP-2 is FDA-approved for single-level ALIF. BMPs belong to the TGF-beta superfamily. They bind to transmembrane serine/threonine kinase receptors, which then phosphorylate intracellular SMAD proteins (specifically SMAD 1, 5, and 8). These form a complex with SMAD 4, translocate to the nucleus, and regulate the transcription of osteogenic genes (e.g., Runx2). They do not act via tyrosine kinases, Wnt/beta-catenin directly as their primary receptor, or cAMP.

Question 1566

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with a recurrence of an unresectable giant cell tumor (GCT) of the sacrum. The multidisciplinary tumor board recommends treatment with denosumab. What is the specific mechanism of action of this medication in the context of a giant cell tumor?

. Directly induces apoptosis of the neoplastic mononuclear cells
. Binds to osteoprotegerin (OPG), preventing it from neutralizing RANKL
. Binds to RANKL, preventing activation of the non-neoplastic giant cells
. Inhibits the vascular endothelial growth factor (VEGF) pathway
. Binds directly to RANK on the surface of neoplastic mononuclear cells

Correct Answer & Explanation

. Directly induces apoptosis of the neoplastic mononuclear cells

Explanation

Giant cell tumor of bone consists of neoplastic mononuclear cells (which express RANK ligand) and reactive, non-neoplastic, osteoclast-like giant cells (which express RANK). Denosumab is a fully human monoclonal antibody that binds directly to RANKL (secreted by the neoplastic stromal cells), preventing it from activating the RANK receptor on the reactive giant cells. This halts their recruitment, formation, and bone-resorbing activity.

Question 1567

Topic: Biology, Genetics & Bone Healing

A 14-year-old boy presents with a history of multiple fractures and anemia. Radiographs demonstrate diffusely dense bones with a 'bone-in-bone' appearance. Genetic analysis reveals a mutation in the TCIRG1 gene. What is the primary cellular defect responsible for this patient's condition?

. Inability of osteoblasts to synthesize mature type I collagen
. Failure of osteoclasts to acidify the Howship lacuna
. Defective mineralization of the osteoid matrix by osteoblasts
. Overactivity of osteoclasts due to excessive RANKL production
. Inability of macrophages to phagocytose necrotic bone

Correct Answer & Explanation

. Inability of osteoblasts to synthesize mature type I collagen

Explanation

The patient has osteopetrosis, a genetic disorder characterized by dense but brittle bones due to defective osteoclast function. The TCIRG1 gene encodes the a3 subunit of the vacuolar H+-ATPase (proton pump), which is essential for osteoclasts to pump protons and acidify the resorption pit (Howship lacuna). Without this acidic environment, hydroxyapatite cannot be dissolved, halting bone resorption.

Question 1568

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with persistent knee pain. Radiographs demonstrate an eccentric, lytic, expansile lesion in the distal femur epiphysis extending to the subchondral bone, with no sclerotic margin. Histological examination reveals numerous multinucleated giant cells distributed evenly throughout a background of mononuclear stromal cells. Which cell type in this lesion is the true neoplastic population, and what is the key molecular target for specific medical therapy?

. Multinucleated giant cells; targeted by RANK
. Mononuclear stromal cells; targeted by RANKL
. Multinucleated giant cells; targeted by VEGF
. Mononuclear stromal cells; targeted by PD-L1
. Macrophages; targeted by M-CSF

Correct Answer & Explanation

. Multinucleated giant cells; targeted by RANK

Explanation

In Giant Cell Tumor of Bone (GCTB), the true neoplastic cells are the mononuclear spindle-shaped stromal cells, not the multinucleated giant cells. These neoplastic stromal cells aberrantly express high levels of Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL), which recruits and stimulates normal circulating monocytes to fuse into the reactive osteoclast-like multinucleated giant cells that cause the aggressive bone resorption. Denosumab, a monoclonal antibody, specifically targets and binds to RANKL, preventing the activation of the giant cells and leading to rapid ossification of the lesion.

Question 1569

Topic: Biology, Genetics & Bone Healing

A 62-year-old man presents with progressive anterolateral bowing of his left tibia. He reports his hat size has increased over the last few years. Laboratory evaluation reveals a markedly elevated serum alkaline phosphatase, but normal serum calcium, phosphorus, and parathyroid hormone levels. What is the fundamental cellular abnormality initiating this disease process?

. Defective mineralization of osteoid by osteoblasts
. Increased resorptive activity of large, hypernucleated osteoclasts
. A mutation in the COL1A1 gene leading to abnormal type I collagen
. Paraneoplastic secretion of parathyroid hormone-related peptide (PTHrP)
. Monoclonal proliferation of plasma cells

Correct Answer & Explanation

. Defective mineralization of osteoid by osteoblasts

Explanation

The patient's clinical presentation (tibial bowing, increasing head size) and laboratory profile (isolated elevation of alkaline phosphatase) are classic for Paget's disease of bone (osteitis deformans). The primary cellular abnormality initiating Paget's disease is intense, focal osteoclastic overactivity. The osteoclasts are markedly enlarged and hypernucleated (sometimes containing up to 100 nuclei). This is followed by a compensatory but disorganized osteoblastic response, leading to structurally weak, woven bone.

Question 1570

Topic: Biology, Genetics & Bone Healing

Which of the following biological descriptions accurately represents primary (strain-free) bone healing?

. It involves endochondral ossification leading to robust callus formation.
. It requires absolute stability and proceeds via cutting cones crossing the fracture site.
. It is typically achieved through intramedullary nailing of diaphyseal fractures.
. It relies heavily on the early proliferation of a hematoma into a soft cartilaginous callus.
. It is primarily regulated by the release of transforming growth factor-beta (TGF-beta) to induce chondrogenesis.

Correct Answer & Explanation

. It involves endochondral ossification leading to robust callus formation.

Explanation

Primary bone healing (also known as direct bone healing) occurs only when there is absolute fracture stability (strain < 2%) and intimate cortical contact, typically achieved via rigid internal fixation (e.g., compression plating). It bypasses the formation of a cartilaginous intermediate and fracture callus. Instead, it proceeds via direct remodeling of lamellar bone by osteoclastic 'cutting cones' that cross the fracture line, followed immediately by osteoblasts laying down new bone. Secondary bone healing involves callus formation and endochondral ossification, which occurs with relative stability (e.g., intramedullary nailing or casting).

Question 1571

Topic: Biology, Genetics & Bone Healing

A 35-year-old woman presents with knee pain. Radiographs reveal an eccentric, lytic lesion in the distal femur extending to the subchondral bone without a sclerotic rim. Biopsy confirms a giant cell tumor of bone. She is treated with denosumab preoperatively. What is the mechanism of action of denosumab in this clinical setting?

. Direct cytotoxic effect on multinucleated giant cells
. Inhibition of vascular endothelial growth factor (VEGF)
. Binding to RANKL, preventing activation of the RANK receptor on osteoclast precursors
. Inhibition of matrix metalloproteinases (MMPs)
. Binding to the RANK receptor, preventing interaction with RANKL

Correct Answer & Explanation

. Direct cytotoxic effect on multinucleated giant cells

Explanation

Denosumab is a human monoclonal antibody that binds to the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). In Giant Cell Tumor of bone (GCT), the neoplastic stromal cells express RANKL, which recruits and activates the reactive multinucleated giant cells (osteoclast-like cells) expressing RANK. By binding RANKL, denosumab prevents the interaction with the RANK receptor, thereby decreasing bone resorption and causing tumor necrosis and ossification.

Question 1572

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with persistent knee pain. Radiographs demonstrate an eccentric, lytic epiphyseal lesion in the distal femur without sclerotic margins. A core needle biopsy reveals mononuclear cells intermixed with multinucleated giant cells. The patient is prescribed denosumab to downstage the tumor prior to surgery. What is the mechanism of action of this medication in the context of this tumor?

. It binds to the RANK receptor on the multinucleated giant cells, directly inhibiting their activity
. It binds to RANKL secreted by the neoplastic mononuclear stromal cells, preventing osteoclast differentiation
. It inhibits vascular endothelial growth factor (VEGF), reducing tumor angiogenesis
. It promotes apoptosis of the neoplastic multinucleated giant cells via p53 activation
. It directly inhibits osteoclast proton pumps, thereby reducing bone resorption

Correct Answer & Explanation

. It binds to the RANK receptor on the multinucleated giant cells, directly inhibiting their activity

Explanation

In giant cell tumor of bone (GCTB), the neoplastic cells are the mononuclear stromal cells, not the giant cells. These stromal cells highly express RANKL. The RANKL stimulates the recruitment and differentiation of non-neoplastic multinucleated giant cells (osteoclast-like cells) which cause extensive bone destruction. Denosumab is a monoclonal antibody that binds to RANKL, preventing it from interacting with the RANK receptor on the multinucleated giant cells, thereby inhibiting their differentiation and osteolytic activity.

Question 1573

Topic: Biology, Genetics & Bone Healing

A 65-year-old man presents with progressive bowing of his right tibia and dull, aching leg pain. Blood tests reveal an isolated, significantly elevated alkaline phosphatase level with normal calcium and phosphorus. Radiographs show cortical thickening, trabecular coarsening, and anterior bowing of the tibia. A biopsy of the bone would most likely demonstrate which of the following histologic features?

. Haphazardly arranged woven bone surrounded by bland fibrous tissue
. A mosaic pattern of lamellar bone with prominent cement lines
. Woven bone trabeculae lined by prominent osteoblasts with multinucleated giant cells in a hemorrhagic stroma
. Islands of cartilage with endochondral ossification extending from the physis
. Spindle cells arranged in a herringbone pattern

Correct Answer & Explanation

. Haphazardly arranged woven bone surrounded by bland fibrous tissue

Explanation

The clinical presentation is classic for Paget's disease of bone (osteitis deformans). The classic histologic finding in the mixed and sclerotic phases of Paget's disease is a 'mosaic' or 'jigsaw puzzle' pattern of lamellar bone with irregular, prominent cement lines. This pattern is the result of erratic and decoupled osteoclast and osteoblast activity. Option A describes fibrous dysplasia. Option C describes an aneurysmal bone cyst or hyperparathyroidism (brown tumor). Option E describes fibrosarcoma.

Question 1574

Topic: Biology, Genetics & Bone Healing

A 68-year-old man presents with lower back pain and fatigue. Radiographs of the lumbar spine and pelvis reveal multiple 'punched-out' lytic lesions without reactive sclerosis. Laboratory studies show mild hypercalcemia and a normocytic anemia. Which of the following diagnostic tests would be most appropriate to confirm the underlying diagnosis and evaluate the extent of skeletal involvement?

. Technetium-99m bone scan and prostate-specific antigen (PSA)
. Serum protein electrophoresis (SPEP) and a whole-body low-dose CT scan
. MRI of the spine and a chest CT scan
. Bone marrow biopsy and a dual-energy x-ray absorptiometry (DEXA) scan
. Positron emission tomography (PET) scan and carcinoembryonic antigen (CEA)

Correct Answer & Explanation

. Technetium-99m bone scan and prostate-specific antigen (PSA)

Explanation

The clinical picture of age, punched-out lytic lesions, hypercalcemia, and anemia strongly suggests multiple myeloma. Serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP) are essential to detect monoclonal paraproteins. To evaluate skeletal involvement, a whole-body low-dose CT scan (or whole-body MRI/PET-CT) is indicated. Technetium-99m bone scans depend on osteoblastic activity; since myeloma lesions are purely osteolytic and suppress osteoblasts, bone scans are classically 'cold' or falsely negative in myeloma.

Question 1575

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with a lytic, expansile lesion in the distal femur extending to the subchondral bone. Biopsy confirms a giant cell tumor of bone. She is treated preoperatively with denosumab to consolidate the lesion. What is the specific mechanism of action of this medication?

. Direct inhibition of the ruffled border of osteoclasts
. Monoclonal antibody binding to RANK ligand (RANKL), preventing osteoclast activation
. Binding to RANK receptor on the osteoclast precursor, inducing apoptosis
. Inhibition of farnesyl pyrophosphate synthase, disrupting osteoclast function
. Activation of osteoprotegerin (OPG), competitively inhibiting RANKL

Correct Answer & Explanation

. Direct inhibition of the ruffled border of osteoclasts

Explanation

Denosumab is a fully human monoclonal antibody that binds directly to RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). By binding RANKL, it prevents RANKL from interacting with the RANK receptor on osteoclasts and their precursors, thereby inhibiting osteoclast formation, function, and survival. Bisphosphonates inhibit farnesyl pyrophosphate synthase.

Question 1576

Topic: Biology, Genetics & Bone Healing

A 68-year-old woman taking oral alendronate for 10 years presents with a 3-month history of dull right thigh pain. Radiographs reveal focal lateral cortical thickening (beaking) and a transverse radiolucent line in the subtrochanteric femur. What is the fundamental alteration in bone physiology responsible for this condition?

. Excessive osteoclastic bone resorption outstripping osteoblastic formation
. Severely suppressed bone turnover leading to the accumulation of physiologic microdamage
. Vitamin D deficiency causing impaired mineralization of osteoid
. A mutation in the type I collagen gene causing structural weakness
. Hyperparathyroidism inducing generalized osteitis fibrosa cystica

Correct Answer & Explanation

. Excessive osteoclastic bone resorption outstripping osteoblastic formation

Explanation

Long-term use of bisphosphonates suppresses normal bone turnover. By inhibiting osteoclastic resorption, targeted remodeling of bone is arrested, which prevents the repair of physiologic microcracks. Over time, this microdamage accumulates, altering the biomechanical properties of the femur and leading to an increased risk of atypical femur fractures (AFFs). These typically begin as tension-sided cortical stress reactions.

Question 1577

Topic: Biology, Genetics & Bone Healing

A researcher is developing a novel therapeutic agent for osteoporosis that directly inhibits the physiological processes at the ruffled border of osteoclasts. Which of the following best describes the primary mechanism by which osteoclasts create the acidic environment necessary for bone resorption at this ruffled border?

. Carbonic anhydrase II generation of hydrogen ions and subsequent active transport via a vacuolar H+-ATPase pump
. Active transport of hydrochloric acid by a local Na+/K+ ATPase pump in exchange for extracellular calcium
. Direct action of TRAP (Tartrate-resistant acid phosphatase) lowering the local pH within the sealed zone
. Binding of RANK-Ligand to the OPG receptor, causing an intracellular surge of lysozymes
. Secretion of Cathepsin K and matrix metalloproteinases that primarily degrade hydroxyapatite crystals

Correct Answer & Explanation

. Carbonic anhydrase II generation of hydrogen ions and subsequent active transport via a vacuolar H+-ATPase pump

Explanation

Osteoclasts resorb bone by tightly adhering to the bone surface (creating a sealed zone) and forming a ruffled border. Within the osteoclast, carbonic anhydrase II catalyzes the conversion of H2O and CO2 into hydrogen ions (H+) and bicarbonate (HCO3-). The hydrogen ions are actively pumped across the ruffled border into the resorption pit by a vacuolar H+-ATPase, creating a highly acidic environment (pH ~4) that dissolves inorganic hydroxyapatite. Once the mineral is dissolved, enzymes like Cathepsin K degrade the remaining organic collagen matrix.

Question 1578

Topic: Biology, Genetics & Bone Healing

A 28-year-old woman presents with knee pain. Radiographs show an eccentric, lytic lesion in the distal femoral epiphysis extending precisely to the subchondral bone. Biopsy confirms a giant cell tumor of bone. Which of the following molecular targets is specifically responsible for the aggressive osteolysis in this tumor and is targeted in its medical management?

. Receptor activator of nuclear factor kappa-B ligand (RANKL)
. Vascular endothelial growth factor (VEGF)
. Platelet-derived growth factor (PDGF)
. Fibroblast growth factor receptor (FGFR)
. Mammalian target of rapamycin (mTOR)

Correct Answer & Explanation

. Receptor activator of nuclear factor kappa-B ligand (RANKL)

Explanation

Giant cell tumor of bone (GCT) is primarily driven by neoplastic mononuclear stromal cells that overexpress RANKL. This overexpression recruits and stimulates normal osteoclast precursors to fuse into reactive, multinucleated giant cells, leading to aggressive and rapid bone resorption. Denosumab, a monoclonal antibody that binds to and neutralizes RANKL, is utilized in the medical management of advanced, unresectable, or recurrent GCTs to inhibit bone destruction and induce ossification of the tumor matrix.

Question 1579

Topic: Biology, Genetics & Bone Healing

Denosumab has revolutionized the non-surgical management of advanced giant cell tumors of bone. What is the precise cellular mechanism of action of this targeted medication?

. It directly inhibits osteoclast ruffled border formation by binding to alphav-beta3 integrins.
. It binds to and neutralizes RANK ligand, preventing its interaction with the RANK receptor on osteoclast precursors.
. It directly induces apoptosis of mature osteoclasts by irreversibly inhibiting farnesyl pyrophosphate synthase.
. It acts as a competitive antagonist at the parathyroid hormone (PTH) receptor on osteoblasts.
. It inhibits matrix metalloproteinases (MMPs) secreted by neoplastic stromal cells.

Correct Answer & Explanation

. It directly inhibits osteoclast ruffled border formation by binding to alphav-beta3 integrins.

Explanation

Denosumab is a fully human monoclonal antibody that specifically targets and binds to RANK Ligand (RANKL). By binding to RANKL, denosumab prevents the ligand from interacting with its designated receptor, RANK, which is located on the surface of osteoclasts and osteoclast precursors. This blockade effectively halts osteoclast formation, function, and survival, thereby rapidly decreasing tumor-induced bone resorption. In contrast, bisphosphonates work by inhibiting farnesyl pyrophosphate synthase, leading to osteoclast apoptosis.

Question 1580

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with knee pain. Radiographs reveal an eccentric, lytic epiphyseal lesion extending to the subchondral bone of the distal femur. Biopsy reveals multinucleated giant cells in a background of mononuclear stromal cells. She is prescribed a medication that binds to a specific ligand to prevent osteoclast activation. What is the target of this medication?

. Osteoprotegerin (OPG)
. Macrophage colony-stimulating factor (M-CSF)
. Vascular endothelial growth factor (VEGF)
. RANK ligand (RANKL)
. RANK receptor

Correct Answer & Explanation

. Osteoprotegerin (OPG)

Explanation

The clinical and radiographic presentation is classic for a Giant Cell Tumor (GCT) of bone. The neoplastic mononuclear stromal cells of GCT express RANKL, which recruits and activates the reactive multinucleated osteoclast-like giant cells that express the RANK receptor. Denosumab is a fully human monoclonal antibody that directly targets and binds to RANK ligand (RANKL), thereby preventing osteoclast activation and subsequent bone destruction. Osteoprotegerin (OPG) is the body's natural decoy receptor for RANKL.

Test Yourself

Switch to an interactive, timed exam simulation to truly master this topic.

On this Page